GLUE MONTE ROSA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MONTE ROSA THERAPEUTICS INC reported revenue of $8.97M (down 61.3% from a year earlier), net income of −$43.4M and diluted EPS of n/a; over the last four quarters revenue was $28.7M and net income −$161M; for the fiscal year ended December 2025 revenue was $124M, up 63.5% on the year before.
GLUE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $124M, gross profit n/a, operating income −$54.2M, net income −$38.6M (margin -31.2%), EPS n/a
- Fiscal year ended Dec 2024: revenue $75.6M, gross profit n/a, operating income −$81.1M, net income −$72.7M (margin -96.1%), EPS n/a
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$143M, net income −$135M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$112M, net income −$109M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$72.9M, net income −$74.0M (margin n/a), EPS −$2.96
GLUE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $8.97M (down 61.3% year over year), net income −$43.4M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $4.21M (down 95.0% year over year), net income −$44.5M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $2.78M (down 95.4% year over year), net income −$46.1M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $12.8M (up 38.5% year over year), net income −$27.1M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $23.2M (up 394.0% year over year), net income −$12.3M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $84.9M (up 7882.0% year over year), net income $46.9M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $60.6M, net income $13.4M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $9.22M, net income −$23.9M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $4.70M, net income −$30.3M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $1.06M, net income −$32.0M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$33.3M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $0, net income −$34.9M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $0, net income −$35.2M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $0, net income −$32.0M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$30.8M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$27.3M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$26.5M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$23.9M, EPS $0.51
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$23.4M, EPS −$6.08
- Quarter ended Sep 30, 2021: revenue n/a, net income −$19.8M, EPS −$0.43
GLUE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$22.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $42.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$43.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$92.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$59.4M, share buybacks n/a
GLUE balance sheet
- Jun 30, 2026: cash $90.1M, total assets $691M, total liabilities $204M, shareholders' equity $487M
- Mar 31, 2026: cash $160M, total assets $736M, total liabilities $215M, shareholders' equity $522M
- Dec 31, 2025: cash $130M, total assets $449M, total liabilities $216M, shareholders' equity $233M
- Sep 30, 2025: cash $208M, total assets $460M, total liabilities $214M, shareholders' equity $246M
- Jun 30, 2025: cash $69.4M, total assets $360M, total liabilities $91.5M, shareholders' equity $268M
- Mar 31, 2025: cash $78.5M, total assets $393M, total liabilities $118M, shareholders' equity $275M
- Dec 31, 2024: cash $224M, total assets $439M, total liabilities $216M, shareholders' equity $223M
- Sep 30, 2024: cash $126M, total assets $315M, total liabilities $110M, shareholders' equity $205M
What is GLUE's revenue?
MONTE ROSA THERAPEUTICS INC reported $28.7M of revenue over its last four quarters, through June 30, 2026.
Is GLUE profitable?
No. MONTE ROSA THERAPEUTICS INC lost $161M over the last four quarters.